Perspectum are proud and valued sponsors of The Elena Baltacha Foundation. Nino shared:

“Through Dr. Saima Ajaz, one of our foundation’s trustees and a close collaborator with the Perspectum team I was introduced to Dr. Rajarshi Banerjee. From our very first meeting, we connected instantly. He is such a humble individual and someone who wholeheartedly supports everything our foundation represents.

Together, we want to raise awareness among young people about the importance of liver health. This mission carries a deeply personal significance: there is a strong connection between Dr. Rajarshi, Perspectum, and my late wife, Elena. She suffered from Primary Sclerosing Cholangitis, a condition that eventually developed into cancer.

The support of Perspectum not only honours Elena’s legacy but also helps us continue our work in educating and inspiring future generations.”

Dr Saima Ajaz

Dr Rajarshi Banerjee co-founded Perspectum in 2012 and has served as its Chief Executive Officer since its inception. Prior to starting Perspectum, he was a research fellow at the University of Oxford, where his work focused on developing magnetic resonance imaging (MRI) techniques for rapid, non-invasive assessment of liver tissue. One of those techniques became the foundation for LiverMultiScan, one of Perspectum’s early flagship products.

Dr Banerjee trained in medicine at Oxford (BM BCh), then continued specialising in cardiovascular health for his PhD. He also has a master’s degree in public health from the London School of Hygiene & Tropical Medicine. He remains clinically active as a consultant physician with Oxford University Hospitals NHS Foundation Trust. His research interests include liver disease phenotyping, both in individuals and populations and integrating imaging-based diagnostics into patient care.

Under his leadership, Perspectum has expanded its tools (such as LiverMultiScan, MRCP+, and now CoverScan) and secured regulatory clearances (e.g. in the US and UK) for multiple imaging-products. One of his priorities has been reducing reliance on biopsy by replacing or augmenting invasive diagnostics with imaging plus AI/ML analytics.

Dr Banerjee is also strongly involved in research studies—especially around chronic metabolic disease, long COVID, and multi-organ impairment. For example, Perspectum through his guidance conducted imaging studies showing organ damage in patients with persistent COVID-19 symptoms, even when their initial illness was mild.

Dr Rajarshi Banerjee

Who is Perspectum

Perspectum has positioned itself as a leader in precision health imaging. CoverScan is helping shift diagnosis and monitoring from invasive or fragmented approaches to ones that are more integrated, quantitative, and patient-friendly. Perspectum is a medical technology company founded in 2012, based initially in Oxford, UK, as a spin-out from the University of Oxford. The company specialises in imaging software and analytics that use MRI data plus AI/machine learning to provide quantitative, non-invasive diagnostics and monitoring for metabolic, liver, long-COVID, and multi-organ diseases. Its suite of tools includes LiverMultiScan (for liver lipid, inflammation, iron etc.), MRCP+ (for biliary/pancreatic duct visualisation) and others.

Perspectum also partners with academic and clinical institutions: in 2025 it formed a collaboration with the London Institute for Healthcare Engineering (part of King’s College London) to push forward imaging innovations for metabolic disease, AI-powered diagnostic tools, and help bring research findings into clinical practice.

What is CoverScan & How It Works

CoverScan is one of Perspectum’s newer platform products. It is a software-as-a-service (SaaS) tool that processes MRI scans (non-contrast, using existing MRI infrastructure — no need for extra hardware or contrast dye) to deliver quantitative metrics across six organs: heart, liver, lungs, kidneys, pancreas, and spleen. From a single MRI exam, it extracts approximately 49 metrics (tissue characteristics, function, size) and compares them to reference ranges. It is multi-parametric MRI plus AI to help detect organ impairment, monitor disease progression, and support more personalized treatment decisions.

Impact & Significance

The influence of Perspectum’s tools, particularly CoverScan, is being felt across several fronts:

Early detection and comprehensive diagnostics
Traditional diagnostics often require separate tests, sometimes invasive ones (like biopsies). CoverScan allows multiple organs to be assessed in one MRI, which speeds up detection of multi-organ problems. This is especially relevant for conditions like Long COVID, metabolic disease, where damage may occur in more than one organ.

Reducing invasive procedures
Because CoverScan is non-invasive and uses MRI + software, it reduces the need for biopsies or multiple separate imaging/referral steps. That can lower patient risk, discomfort, and cost.

Dr Rajarshi Banerjee presenting to the guests at The Elena Baltacha Foundation event, ‘An Evening with Marion Bartoli’.

Supporting personalised medicine & monitoring
The quantitative metrics allow tracking over time, which helps clinicians monitor disease progression or response to treatment and tailor interventions more individually.

Regulatory and reimbursement advances
The fact that CoverScan secured regulatory clearances (UKCA, MHRA, FDA) helps with adoption in health systems. Also, the Company has already been granted reimbursement codes or access under Medicare / commercial plans in certain U.S. areas for some of its liver-related products (LiverMultiScan) which shows it is making inroads in turning advanced imaging into something that is actually used in routine care.

Research contributions and large-scale studies
Perspectum is involved in research studies (for example, the COVERSCAN study for long COVID with the National Consortium for Intelligent Medical Imaging). These studies provide evidence about multi-organ impairment, risk factors etc. That helps define how to use these tools in real practice.